



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	1	of	12	Attorney Docket Number	RUJ-001CNCP2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-4,474,893	10-02-1984	Reading	
	A2*	US-4,946,778	08-07-1990	Ladner et al.	
	A3*	US-4,954,617	09-04-1990	Fanger et al.	
	A4*	US-5,455,030	10-03-1995	Ladner et al.	
	A5*	US-5,476,786	12-19-1995	Huston	
	A6*	US-5,545,807	08-13-1996	Surani et al.	
	A7*	US-5,698,679	12-16-1997	Nemazee	
	A8*	US-5,869,057	02-09-1999	Rock	
	A9*	US-5,876,917	03-02-1999	Hart et al.	
	A10*	US-5,922,845	07-13-1999	Deo et al.	
	A11*	US-6,080,409	06-27-2000	Laus et al.	
	A12*	US-6,117,977	09-12-2000	Lasky et al.	
	A13*	US-6,277,959	08-21-2001	Valladeau et al.	
	A14*	US-6,340,569	01-22-2002	Ball et al.	
	A15*	US-6,432,666	08-13-2002	Hart et al.	
	A16*	US-6,479,247-A1	11-12-2002	Hart et al.	
	A17*	US-20020187131-A1	12-12-2002	Hawiger et al.	
	A18*	US-6,756,478-A1	06-29-2004	Valladeau et al.	
	A19*	US-20040001853-A1	01-01-2004	George et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	WO-86/01533-A1	03-13-1986	Celltech Limited		
	B2	WO-88/00052-A1	01-14-1988	Trustees of Dartmouth College		
	B3	WO-92/07579-A1	05-14-1992	The Children's Medical Center Corporation		
	B4	WO-92/03918-A1	03-19-1992	Genpharm International, Inc.		
	B5	WO-93/04187-A1	03-04-1993	Medical Research Council		
	B6	WO-93/12227-A1	06-24-1993	Genpharm International, Inc.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Express Mail Label No. EM 192 978 552 US Dated: January 9, 2009

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
				Attorney Docket Number	RUJ-001CNCP2
Sheet	3	of	12		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B13	WO-99/02562-A1	01-21-1999	Schering Corporation		
	B14	WO-99/16455-A1	04-08-1999	The Austin Research Institute		
	B15	WO-99/24554-A2	05-20-1999	University of Pittsburgh		
	B16	WO-99/47673-A2	09-23-1999	Schering Corporation		
	B17	WO-99/55369-A1	11-04-1999	Smithkline Beecham Corporation		
	B18	WO-99/58678-A2	11-18-1999	Micromet GmbH		

Examiner Signature	Date Considered
-----------------------	--------------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	Page No.
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	B19	WO-00/00156-A2	01-06-2000	Trustees of Dartmouth College		
	B20	WO-00/00592-A1	01-06-2000	Bae, Yong Soo et al.		
	B21	WO-00/18803-A2	04-06-2000	Schering Corporation		
	B22	WO-00/63251-A1	10-26-2000	Katholieke Universiteit Nijmegen		
	B23	WO-01/25492-A1	04-12-2001	Biosite Diagnostics Inc. et al.		
	B24	WO-01/85798-A2	11-15-2001	Medarex, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	6	of	12	Attorney Docket Number	RUJ-001CNC2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C1	Apostolopoulos, Vasso et al, "Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses," <i>Vaccine</i> , Vol. 18:3174-3184 (2000)		
	C2	Austyn, Jonathan M. et al., "Isolation and Characterization of Dendritic Cells from Mouse Heart and Kidney," <i>Journal of Immunology</i> , Vol. 152:2401-2410 (1994)		
	C3	Berard, Frederic et al, "Cross-Priming of Naive CD8 T Cells against Melanoma Antigens Using Dendritic Cells Loaded with Killed Allogeneic Melanoma Cells," <i>J. Exp. Med.</i> , Vol. 192(11):1535-1543 (2000)		
	C4	Berlyn, Kathleen A. et al, "Generation of CD4 ⁺ and CD8 ⁺ T Lymphocyte Responses by Dendritic Cells Armed with PSA/Anti-PSA (Antigen/Antibody) Complexes," <i>Clinical Immunology</i> , Vol. 101(3):276-283 (2001)		
	C5	Bird, Robert E. et al, "Single-Chain Antigen-Binding Proteins," <i>Science</i> , Vol. 242(4877):423-426 (1988)		
	C6	Bonifaz, Laura et al., "Efficient Targeting of Protein Antigen to the Dendritic Cell Receptor DEC-205 in the Steady State Leads to Antigen Presentation on Major Histocompatibility Complex Class II Products and Peripheral CD8 ⁺ T Cell Tolerance," <i>J. Exp. Med.</i> , Vol. 196(12):1627-1938 (2002)		
	C7	Breel, M. et al., "Subpopulations of lymphoid and non-lymphoid cells in bronchus-associated lymphoid tissue (BALT) of the mouse," <i>Immunology</i> , Vol. 63:657-662 (1988)		
	C8	Brennan, Maureen et al, "Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G1 Fragments," <i>Science</i> , Vol. 229:81-83 (1985)		
	C9	Casset, Florence et al., "A peptide mimetic of an anti-CD4 monoclonal antibody in rational design," <i>Biochemical and Biophysical Research Communications</i> , Vol. 307:198-205 (2003)		
	C10	Chen, Wen-Ji et al., "NPXY, a Sequence Often Found in Cytoplasmic Tails, Is Required for Coated Pit-mediated Internalization of the Low Density Lipoprotein Receptor," <i>The Journal of Biological Chemistry</i> , Vol. 265(6):3116-3123 (1990)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	7	of	12	Attorney Docket Number	RUJ-001CNCP2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C11	Chen, Yvonne et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen," <i>J. Mol. Biol.</i> , Vol. 293:865-881 (1999)	
	C12	Chien, Nadine C. et al., "Significant structural and functional change of an antigen-binding site by a distant amino acid substitution: Proposal of a structural mechanism," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 86:5532-5536 (1989)	
	C13	Collawn, James F. et al., "Transferrin Receptor Internalization Sequence YXRF Implicates a Tight Turn as the Structural Recognition Motif for Endocytosis," <i>Cell</i> , Vol. 63:1061-1072 (1990)	
	C14	Cox, John C. et al., "Adjuvants - a classification and review of their modes of action," <i>Vaccine</i> , Vol. 15(3):248-256 (1997)	
	C15	De Maagd, R.A. et al., "The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial cell antibodies," <i>Immunology</i> , Vol. 54:745-754 (1985)	
	C16	De Pascalis, Roberto et al., "Grafting of 'Abbreviated' Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," <i>The Journal of Immunology</i> , Vol. 169:3076-3084 (2002)	
	C17	Drickamer, K. et al., "Biology of animal lectins," <i>Annu. Rev. Cell Biol.</i> , Vol. 9:237-264 (1993)	
	C18	Ezekowitz, R. Alan B. et al., "Molecular Characterization of the Human Macrophage Mannose Receptor: Demonstration of Multiple Carbohydrate Recognition-like Domains and Phagocytosis of Yeasts in Cos-1 Cells," <i>J. Exp. Med.</i> , Vol. 172:1785-1794 (1990)	
	C19	Frleta, Davor et al., "Class II-targeted antigen is superior to CD40-targeted antigen at stimulating humoral responses in vivo," <i>International Immunopharmacology</i> , Vol. 1:265-275 (2001)	
	C20	Galfre, G. et al., "Antibodies to major histocompatibility antigens produced by hybrid cell lines," <i>Nature</i> , Vol. 266(7):550-552 (1977)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	8	of	12	Attorney Docket Number	RUJ-001CNCP2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C21	Geissmann, Frédéric et al, "A Subset of Human Dendritic Cells Expresses IgA Fc Receptor (CD89), Which Mediates Internalization and Activation Upon Cross-Linking by IgA Complexes," <i>The Journal of Immunology</i> , Vol. 166:346-352 (2001)		
	C22	Glennie, Martin J. et al, "Preparation and Performance of Bispecific F(ab') ₂ Antibody Containing Thioether-Linked Fab'γ Fragments," <i>The Journal of Immunology</i> , Vol. 139(7):2367-2375 (1987)		
	C23	Guo, Ming et al., "A Monoclonal Antibody to the DEC-205 Endocytosis Receptor on Human Dendritic Cells," <i>Human Immunology</i> , Vol. 61:729-738 (2000)		
	C24	Hawiger, Daniel et al, "Dendritic Cells Induce Peripheral T Cell Unresponsiveness Under Steady State Conditions In Vivo," <i>J. Exp. Med.</i> , Vol. 194(6):769-779 (2001)		
	C25	He, Li-Zhen et al, "A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin β," <i>Clinical Cancer Research</i> , Vol. 10:1920-1927 (2004)		
	C26	He, Lizhen et al, "An Antigen Presenting Cell-Targeted Cancer Vaccine that Elicits CD4 and CD8 Effector Responses to the hCGβ Tumor-Associated Antigen," <i>Proceedings of the American Association for Cancer Research</i> , Vol. 44, 2nd ed., pg. 167 (2003)		
	C27	Inaba, Kayo et al., "Tissue Distribution of the DEC-205 Protein That Is Detected by the Monoclonal Antibody NLDC-145, I. Expression on Dendritic Cells and Other Subsets of Mouse Leukocytes," <i>Cellular Immunology</i> , Vol. 163:148-156 (1995)		
	C28	Ishizaki, Jun et al., "Molecular Cloning of Pancreatic Group I Phospholipase A ₂ Receptor," <i>The Journal of Biological Chemistry</i> , Vol. 269(8):5897-5904 (1994)		
	C29	Janeway, Charles A. Jr. et al., "Localized regions of hypervariable sequence form the antigen-binding site," <i>Immunobiology</i> , 6 th Edition, Garland Science, Chpt. 3, pgs. 110-112 (2004)		
	C30	Jiang, Wanping et al., "The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing," <i>Nature</i> , Vol. 375:151-155 (1995)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	9	of	12	Attorney Docket Number	RUJ-001CNCP2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C31	Karpovsky, Boris et al, "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fcγ Receptor Antibodies," <i>Journal of Experimental Medicine</i> , Vol. 160:1686-1701 (1984)		
	C32	Kawakami, Yutaka et al, "The Use of Melanosomal Proteins in the Immunotherapy of Melanoma," <i>Journal of Immunotherapy</i> , Vol. 21(4):237-246 (1998)		
	C33	Kobayashi, Hiroyuki et al, "Tryptophan H33 plays an important role in pyrimidine (6-4) pyrimidone photoproduct binding by a high-affinity antibody," <i>Protein Engineering</i> , Vol. 12(10):879-884 (1999)		
	C34	Kraal, Georg et al., "Langerhans' Cells, Veiled Cells, and Interdigitating Cells in the Mouse Recognized by a Monoclonal Antibody," <i>J. Exp. Med.</i> , Vol. 163:981-997 (1986)		
	C35	Lambeau, Gérard et al., "Cloning and Expression of a Membrane Receptor for Secretory Phospholipases A ₂ ," <i>The Journal of Biological Chemistry</i> , Vol. 269(3):1575-1578 (1994)		
	C36	Lamminmäki, Urpo et al., "Crystal Structure of a Recombinant Anti-estradiol Fab Fragment in Complex with 17β-Estradiol," <i>The Journal of Biological Chemistry</i> , Vol. 276(39):36687-36694 (2001)		
	C37	Liu, Margaret A. et al, "Heteroantibody duplexes target cells for lysis by cytotoxic T lymphocytes," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 82:8648-8652 (1985)		
	C38	Lonberg, Nils et al, "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , Vol. 368:856-859 (1994)		
	C39	Lu, Lina et al., "Propagation of Dendritic Cell Progenitors from Normal Mouse Liver Using Granulocyte/Macrophage Colony-stimulating Factor and Their Maturation Development in the Presence of Type-1 Collagen," <i>J. Exp. Med.</i> , Vol. 179:1823-1834 (1994)		
	C40	MacCallum, Robert M. et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topography," <i>J. Mol. Biol.</i> , Vol. 262:732-745 (1996)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	10	of	12	Attorney Docket Number	RUJ-001CNC2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C41	McKay, Paul F. et al., "The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family," <i>Eur. J. Immunol.</i> , Vol. 28:4071-4083 (1998)	
	C42	McKown, Kevin M. et al., "Lack of Efficacy of Oral Bovine Type II Collagen Added to Existing Therapy in Rheumatoid Arthritis," <i>Arthritis & Rheumatism</i> , Vol. 42 (6):1204-1208 (1999)	
	C43	Mestas, Javier et al., "Of Mice and Not Men: Differences between Mouse and Human Immunology," <i>The Journal of Immunology</i> , Vol. 172:2731-2738 (2004)	
	C44	Monteiro, Renato C. et al, "Molecular Heterogeneity of Fcα Receptors Detected by Receptor-Specific Monoclonal Antibodies," <i>The Journal of Immunology</i> , Vol. 148(6):1764-1770 (1992)	
	C45	Noorman, Femke et al, "Monoclonal antibodies against the human mannose receptor as a specific marker in flow cytometry and immunohistochemistry for macrophages," <i>Journal of Leukocyte Biology</i> , Vol. 61:63-72 (1997)	
	C46	Nossal, "Immunologic Tolerance," <i>Fundamentals of Immunology</i> , 2 nd Edition, Paven Press Ltd., W.E. Paul (Ed.), Chpt. 19, pgs. 571-586 (1989)	
	C47	Nouri-Shirazi, Mahyar et al, "Dendritic Cells Capture Killed Tumor Cells and Present Their Antigens to Elicit Tumor-Specific Immune Response," <i>The Journal of Immunology</i> , Vol. 165:3797-3803 (2000)	
	C48	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies," <i>Behring Inst. Mitt.</i> , Vol. 78:118-132 (1985)	
	C49	Potter, Kathleen N. et al, "Evidence for Involvement of a Hydrophobic Patch in Framework Region 1 of Human V4-34-Encoded Igs in Recognition of the Red Blood Cell I Antigen," <i>The Journal of Immunology</i> , Vol. 169:3777-3782 (2002)	
	C50	Puré, Ellen et al., "Antigen Processing by Epidermal Langerhans Cells Correlates with the Level of Biosynthesis of Major Histocompatibility Complex Class II Molecules and Expression of Invariant Chain," <i>J. Exp. Med.</i> , Vol. 172:1459-1469 (1990)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	11	of	12	Attorney Docket Number	RUJ-001CNCP2

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	C51	Ramakrishna, Vanky et al, "Mannose Receptor Targeting of Tumor Antigen pmel17 to Human Dendritic Cells Directs Anti-Melanoma T Cell Responses via Multiple HLA Molecules," <i>The Journal of Immunology</i> , Vol. 172:2845-2852 (2004)		
	C52	Ramakrishna, Venky et al, "Synergistic Role of TLR Agonists in T Cell-Mediated Immunity Induced by Mannose Receptor Antibody Targeting of Tumor Antigens to Human DCs," <i>J. Immunother.</i> , Vol. 28(6):658 (2005)		
	C53	Rudikoff, Stuart et al, "Single amino acid substitution altering antigen-binding specificity," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 79:1979-1983 (1982)		
	C54	Sallusto, Federica et al, "Dendritic Cells Use Macropinocytosis and the Mannose Receptor to Concentrate Macromolecules in the Major Histocompatibility Complex Class II Compartment: Downregulation by Cytokines and Bacterial Products," <i>J. Exp. Med.</i> , Vol. 182:389-400 (1995)		
	C55	Schjetne, Karoline W. et al., "Delivery of Antigen to CD40 Induces Protective Immune Responses against Tumors," <i>The Journal of Immunology</i> , Vol. 178:4169-4176 (2007)		
	C56	Spack, E.G., "Antigen-specific therapies for the treatment of multiple sclerosis: a clinical trial update," <i>Expert Opin. Investig. Drugs</i> , Vol. 6(11):1715-1727 (1997)		
	C57	Steinman, Ralph M., "The Dendritic Cell System and Its Role in Immunogenicity," <i>Annu. Rev. Immunol.</i> , Vol. 9:271-296 (1991)		
	C58	Swiggard, William J. et al., "DEC-205, a 205-kDa Protein Abundant on Mouse Dendritic Cells and Thymic Epithelium That is Detected by the Monoclonal Antibody NLDC-145: Purification, Characterization, and N-Terminal Amino Acid Sequence," <i>Cellular Immunology</i> , Vol. 165:302-311 (1995)		
	C59	Taylor, Lisa D. et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , Vol. 20(23):6287-6295 (1992)		
	C60	Taylor, Maureen E. et al., "Contribution to Ligand Binding by Multiple Carbohydrate-recognition Domains in the Macrophage Mannose Receptor," <i>The Journal of Biological Chemistry</i> , Vol. 267(3):1719-1726 (1992)		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/800,023-Conf. #9210
				Filing Date	March 12, 2004
				First Named Inventor	Daniel HAWIGER
				Art Unit	1644
				Examiner Name	R. B. Schwadron
Sheet	12	of	12	Attorney Docket Number	RUJ-001CNCP2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C61	Taylor, Maureen E. et al., "Structural Requirements for High Affinity Binding of Complex Ligands by the Macrophage Mannose Receptor," <i>The Journal of Biological Chemistry</i> , Vol. 268(1):399-404 (1993)	
	C62	Tempest, Philip R. et al., "A Humanized Anti-Tumor Necrosis Factor- α Monoclonal Antibody That Acts as a Partial, Competitive Antagonist of the Template Antibody," <i>Hybridoma</i> , Vol. 13(3):183-190 (1994)	
	C63	Tjoa, Benjamin A. et al., "Development of dendritic-cell based prostate cancer vaccine," <i>Immunology Letters</i> , Vol. 74:87-93 (2000)	
	C64	Tufveson, G. et al., "New Immunosuppressants: Testing and Development in Animal Models and the Clinic: with Special Reference to DSG," <i>Immunological Reviews</i> , Vol. 136(1):99-109 (1993)	
	C65	Tütting, Thomas et al., "Autologous Human Monocyte-Derived Dendritic Cells Genetically Modified to Express Melanoma Antigens Elicit Primary Cytotoxic T Cell Responses In Vitro: Enhancement by Cotransfection of Genes Encoding the Th1-Biasing Cytokines IL-12 and IFN- α ," <i>The Journal of Immunotherapy</i> , Vol. 160:1139-1147 (1998)	
	C66	Wallace, Paul K. et al., "Exogenous antigen targeted to Fc γ RI on Myeloid cells is presented in association with MHC class I," <i>Journal of Immunological Methods</i> , Vol. 248:183-194 (2001)	
	C67	Wang, Hui et al., "Rapid antibody responses by low-dose, single-step, dendritic cell-targeted immunization," <i>PNAS</i> , Vol. 96(2):847-852 (2000)	
	C68	Ward, E. Sally et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , Vol. 341:544-546 (1989)	
	C69	You, Zhaoyang et al., "Targeting Dendritic Cells to Enhance DNA Vaccine Potency," <i>Cancer Research</i> , Vol. 61:3704-3711 (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ** CITE NO.: Those document(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.